EP0843671A1 - Composes heterocycliques et compositions pharmaceutiques a base desdits composes - Google Patents

Composes heterocycliques et compositions pharmaceutiques a base desdits composes

Info

Publication number
EP0843671A1
EP0843671A1 EP96925710A EP96925710A EP0843671A1 EP 0843671 A1 EP0843671 A1 EP 0843671A1 EP 96925710 A EP96925710 A EP 96925710A EP 96925710 A EP96925710 A EP 96925710A EP 0843671 A1 EP0843671 A1 EP 0843671A1
Authority
EP
European Patent Office
Prior art keywords
alkyl
alkoxy
alkylamino
benzyl
dimethoxyquinazoline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP96925710A
Other languages
German (de)
English (en)
Inventor
George Stuart Glaxo Wellcome Plc Cockerill
Malcolm Clive Glaxo Wellcome Plc Carter
Stephen Karl Glaxo Wellcome plc McKEOWN
Sadie Vile
Martin John Glaxo Wellcome plc PAGE
Alan Thomas Long Lodge Cottage HUDSON
Paul Barraclough
Karl Witold 6 Northstead Road FRANZMANN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of EP0843671A1 publication Critical patent/EP0843671A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Definitions

  • the present invention relates to a series of substituted heteroaromatic compounds, methods for their preparation, pharmaceutical compositions containing them and their use in medicine.
  • the invention relates to quinoline and quinazoline derivatives which exhibit protein tyrosine kinase inhibition.
  • Protein tyrosine kinases catalyse the phosphorylation of specific tyrosyl residues in various proteins involved in the regulation of cell growth and differentiation (A.F.Wilks, Progress in Growth Factor Research, 1990 (2), 97-111).
  • Tyrosine kinases can be broadly classified as growth factor receptor (e.g. EGF-R, PDGF-R, FGF-R and erbB-2) or non-receptor (e.g. src, bcr-abl) kinases. Inappropriate or uncontrolled activation of many of these kinases i.e. aberrant tyrosine kinase activity, for example by over-expression or mutation, has been shown to result in uncontrolled cell growth.
  • Aberrant activity of protein tyrosine kinases such as c-erbB-2, c-src, p56lck, EGF- R, PDGF-R, and zap70 have been implicated in human malignancies.
  • Aberrant EGF-R activity has, for example, been implicated in cancers of the head and neck, and aberrant c-erbB-2 activity in breast, ovarian, non-small cell lung, pancreatic, gastric and colon cancers.
  • Inhibitors of protein tyrosine kinase should therefore provide a treatment for tumours such as those outlined above.
  • thrombosis (Salari et al, FEBS; 1990, 263f1V 104-108) and nervous system diseases (Ohmichi et al, Biochemistry, 1992, 3 . , 4034-4039).
  • Inhibitors of the specific tyrosine kinases involved in these diseases eg PDGF-r in restenosis and EGF-r in psoriasis, should lead to novel therapies for such disorders.
  • P56lck and zap 70 are indicated in disease conditions in which T cells are hyperactive e.g. rheumatoid arthritis, autoimmune disease, allergy, asthma and graft rejection.
  • EP0602851 discloses quinazoline derivatives of the formula (1) :
  • each RA includes hydroxy, amino, ureido, hydroxyamino, trifluoromethoxy, (1-4C)alkyl, (1-4C) alkoxy and (1-3C) alkenedioxy; and Q is a 9 or 10-membered bicyclic heterocyclic moiety containing one or two nitrogen atoms and optionally containing a further heteroatom selected from nitrogen, oxygen or sulphur, or Q is a 9 or 10-membered bicyclic aryl moiety, the heterocyclic or aryl moiety optionally bearing one or two substituents selected from halogeno, hydroxy, oxo, amino, nitro, carbamoyl, (1-4C) alkyl, (1-4C) alkoxy, (1-4C) alkylamino, di-[(1-4C) alkyljamino and (2-4C) alkanoylamino.
  • the compounds are claimed to be inhibitors of the EGF tyrosine kinase receptor
  • European Patent Application 0520722A discloses a class of quinazoline derivatives having antitumour activity and having the formula (2)
  • RA is hydrogen, trifluoromethyl or nitro
  • n is 1 and R ⁇ is halogeno, trifluoromethyl, nitro, cyano, (1-4C)alkyl, (1-4C)alkoxy, N-(1- 4C)alkylamino, , -di-((1-4C)alkyl)amino, (1-4C)alkylthio, (1-4C)alkylsulphinyl or (1-4C)alkylsulph- onyl.
  • These compounds are claimed to be inhibitors of the EGF tyrosine kinase receptor and other unspecified tyrosine kinases.
  • EP 0566226A discloses quinazoline derivatives of the formula (3):
  • n is 1 or 2 and each R B includes; hydrogen, hydroxy, halogeno, trifluoromethyl, amino, nitro, cyano and (1-4C) alkyl.
  • the compounds are claimed to be inhibitors of the EGF tyrosine kinase receptor and other unspecified tyrosine kinases.
  • EP0635498 discloses quinazolines of the formula (4)
  • R 1 includes hydroxy, amino, hydroxyamino, (1-4C)alkoxy, (1-4C) alkylamino and di-[(1-4C)alkyl]amino
  • R2 includes independently hydrogen, hydroxy, halogeno, (1-4C)alkyl, (1-4C)alkoxy or (2-4C) alkanoylamino
  • n is 1, 2 or 3
  • R ⁇ is halogeno.
  • EP0635507 discloses tricyclic derivatives of the formula (5) :
  • R 1 and R 2 together form specified optionally substituted groups containing at least one heteroatom so as to form a 5 or 6 membered ring
  • R ⁇ includes independently hydrogen, hydroxy, halogeno, (1-4C)alkyl, (1-4C) alkoxy di-[(1-4C)alkyl]amino, or (2-4C)alkanoylamino.
  • the present invention envisages that other disorders mediated by protein tyrosine kinase activity may be treated effectively by inhibition of the appropriate protein tyrosine kinase activity
  • protein tyrosine kinases such as c-erbB-2, c-erbB-4, c-src, p56lck, EGF-R, fyn, cdk2, PDGF-R, and zap70 protein tyrosine kinases.
  • the present invention envisages that disorders mediated by protein tyrosine kinase activity may be treated effectively by inhibition of the appropriate protein tyrosine kinase activity in a preferential manner.
  • a further object of the present invention is to provide compounds useful in the treatment of protein tyrosine kinase related diseases which minimise undesirable side-effects in the recipient.
  • the present invention relates to certain quinoline and quinazoline derivatives which may be used to treat disorders mediated by protein tyrosine kinases and in particular have anti-cancer properties. More particularly, the compounds of the present invention are potent inhibitors of protein tyrosine kinases such as c-erbB- 2, c-erbB-4, EGF-R, c-src, p56lck, fyn, cdk2, PDGF, and zap 70 thereby allowing chemical management of particular diseased tissues.
  • the present invention envisages, in particular, the treatment of human malignancies, for example breast, stomach, ovary, colon, lung and pancreatic tumours, especially those driven by c-erbB-2, using the compounds of the present invention.
  • the invention includes compounds which are highly active against the c-erbB-2 protein tyrosine kinase in preference to the EGF receptor kinase hence allowing treatment of c-erbB-2 driven tumours.
  • the present invention envisages that disorders mediated by protein tyrosine kinase activity may be treated effectively by inhibition of the appropriate protein tyrosine kinase activity in a relatively selective manner, thereby minimising potential side effects.
  • Certain compounds of the present invention for example 4-(1-benzyl-5- indolylamino)-6,7-dimethoxyquinazoline and 4-(1-benzyl-5-indolylamino)- quinazoline have the unexpected advantage of being highly selective for c-erbB-2 over EGF, in contrast to compounds of the prior art which show little activity towards c-erbB-2 and no selectivity towards this tyrosine kinase.
  • the 4-(5-indolylamino)-6,7-dimethoxyquinazoline inhibits EGF to a much greater extent than it inhibits c-erbB-2, and the c-erbB-2 activity is relatively poor.
  • Y is a group W(CH2), (CH2)W or W in which W is O, S(O) m wherein m is 0, 1 or 2, or NR a wherein R a is hydrogen or a C ⁇
  • U represents a 5 to 10-membered mono or bicyclic ring system in which one or more of the carbon atoms is optionally replaced by a heteroatom independently selected from N, O and S, wherein the ring system is substituted by at least one independently selected R ⁇ group and is optionally substituted by at least one independently selected R 4 group;
  • R1 , R2, R3 and R ⁇ ' are the same or different and are each selected from amino, hydrogen, halogen, hydroxy, nitro, carboxy, trifluoromethyl, trifluoromethoxy, carbamoyl, ureido, C ⁇ .Q alkyl, C-j.8 alkoxy, C3.8 cycloalkoxyl, C4.8 alkylcyclo alkoxy, C-j_8 alkoxycarbonyl, N-C ⁇
  • alkylamino di[C-
  • _4 alkoxy ,N-di-[C-
  • _4 alkylamino N,N-di-[C ⁇ _ alkyl]carbamoyl-C ⁇ _4 alkylamino, amino-C2-4 alkylamino, C-j_4 alkylamino-C2-4 alkylamino, di-[C-j ⁇ alkylamino-C2_4 alkylamino, phenyl-C-j ⁇ alkylamino, phenoxy-C2_4 alkylamino, anilino-C2_4 alkylamino, phenylthio-C2-4 alkylamino, C2-4 alkanoylamino, C-j_4 alkoxycarbonylamino, C-
  • each R 6 is independently a group ZR 7 wherein Z is joined to R 7 through a (CH2)p group in which p is 0, 1 or 2 and Z represents a group V(CH2), V(CF2), (CH2)V, (CF2)V, V(CRR ' ), V(CHR) or V where R and R ' are each C ⁇ alkyl and in which V is a hydrocarbyl group containing 0,1 or 2 carbon atoms, carbonyl, CH(OH), sulphonamide, amide, O, S(O) m or NR D where R D is hydrogen or R D is C-
  • R 6 is a group ZR 7 in which Z is NR b , and NR b and R 7 together form an optionally substituted 5, 6, 7, 8, 9 or 10-membered carbocyclic or heterocyclic moiety.
  • R 1 , R 2 and R 3 are each selected from amino, hydrogen, halogen, hydroxy, nitro, C-
  • R1 and R 2 or R1 and R 3 together form an optionally substituted methylenedioxy or ethylenedioxy group;
  • R 3 ' is hydrogen;
  • R 4 is hydrogen, hydroxy, halogen, C-
  • R 5 is hydrogen, C ⁇
  • Z is absent or represents CH 2 , oxygen, S(O) m , wherein m is 0, 1 or 2, or NR D wherein R D is hydrogen or R D is C-
  • R 7 is an optionally substituted phenyl, benzyl, pyridyl, dioxolanyl, phenoxy, benzyloxy, phenylamino, benzylamino, phenymercapto or benzylmercapto group, preferably a phenyl, fluorophenyl, pyridyl, 1 ,3-dioxolanyl or benzyl group.
  • R 6 R 7 .
  • R 1 , R 2 and R 3 are each selected from hydroxy, C- ⁇ _4 alkyl, C ⁇
  • R ⁇ is in the ring which is remote from Y when U represents a bicyclic group.
  • X is N.
  • Y is NRb, NRb(CH2), or (CH2)NR b , preferably Y is NR b .
  • Heterocyclic groups comprise one or more rings which may be saturated, unsaturated or aromatic and which may independently contain one or more heteroatoms in each ring.
  • Carbocyclic groups comprise one or more rings which may be independently saturated, unsaturated or aromatic and which contain only carbon and hydrogen.
  • X is nitrogen
  • Y is a group NR wherein R is hydrogen or methyl, preferably hydrogen.
  • R " * and R 2 are independently hydrogen; C ⁇ _4 alkyl, such as methyl; or
  • R 3 and R 3 ' are independently hydrogen, methyl or methoxy.
  • R 4 is hydrogen, halogen or methyl, preferably R 4 is hydrogen.
  • R5 is hydrogen or methyl.
  • R 6 is phenyl, fluorophenyl, phenethyl, benzyl, pyridyl, phenylsulphonyl, benzylsulphonyl, phenoxy, benzyloxy or 1 ,3-dioxolanyl.
  • One or both of the rings comprising the mono or bicyclic ring system may be aromatic or non-aromatic.
  • the R 4 and R ⁇ groups may be bound to the ring system by either a carbon atom or a heteroatom of the ring system.
  • the ring system itself may be bound to the bridging group Y which is linked to the 4- position of the quinoline or quinazoline skeleton by a carbon atom or a heteroatom.
  • the R 4 and R ⁇ groups may be bound to either ring when U represents a bicyclic ring system, but these groups are preferably bound to the ring which is not bound to the bridging group Y in such a case.
  • Suitable mono or bicyclic groups U which are ultimately linked to the 4-position of the quinoline or quinazoline include: isoindenyl, indenyl, indanyl, naphthyl, 1,2-dihydronaphthyl or 1,2,3,4-tetrahydronaphthyl, pyrrolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, furanyl, 2H-pyranyl, thiophenyl, 1H-azepinyl, oxepinyl, thiepinyl, azocinyl, 2H-oxocinyl, thieno[2,3-b] furanyl, thianaphthenyl, indolyl, indolinyl, isioindolyl, isoindolinyl, indolizinyl, 1H-benzimidazolyl, 2,3- dihydro
  • U represents an indolyl, isoindolyl, indolinyl, isoindolinyl, IJH-indazolyl, 2,3- dihydro-IJd-indazolyl, IH-benzimidazolyl, 2,3-dihydro-IH-benzimidazolyl or IM- benzotriazolyl group.
  • the 5, 6, 7, 8, 9 or 10-membered heterocyclic moiety is selected from the group comprising: furan, dioxolane, thiophene, pyrrole, imidazole, pyrrolidine, pyran, pyridine, pyrimidine, morpholine, piperidine, oxazoline, oxazolidine, thiazole, thiadiazole, benzofuran, indole, isoindole, quinazoline, quinoline and isoquinoline.
  • the 5, 6, 7, 8, 9 or 10-membered carbocyclic moiety is selected from the group comprising: phenyl, benzyl, indene, naphthalene, tetralin, decalin, cyclopentyl, cyclohexyl and cycloheptyl.
  • halo is meant fluoro, chloro, bromo or iodo.
  • Alkyl groups containing three or more carbon atoms may be straight, branched or cyclised.
  • the optional substitutents for the carbocyclic or heterocyclic moiety, which may be present at any available position of said moiety are selected from the group comprising:
  • R 8 and R 9 are independently selected from the group comprising hydrogen, C ⁇ alkyl, C ⁇ cycloalkyl, aryl, a 5- or 6-membered saturated or unsaturated heterocyclic ring which may be the same or different and which contains one or more heteroatoms which are selected from N, O or S, with the proviso that the heterocyclic ring does not contain two adjacent O or S atoms.
  • the optional substitutents for the carbocyclic or heterocyclic moiety are selected from the group comprising morpholine, piperazine, piperidine, pyrrolidine, tetrahydrofuran, dioxolane, oxothiolane and oxides thereof, dithiolane and oxides thereof, dioxane, pyridine, pyrimidine, pyrazine, pyridazine, furan, thiofuran, pyrrole, triazine, imidazole, triazole, tetrazole, pyrazole, oxazole, oxadiazole and thiadiazole.
  • optional substituents for the carbocyclic or heterocyclic moiety and also for other optionally substituted groups include, but are not limited to, hydroxy, halogen, trifluoromethyl, trifluoromethoxy, nitro, amino, cyano, C-
  • Preferred compounds of the present invention include:
  • Particularly preferred compounds of the present invention include:
  • Salts of the compounds of the present invention may comprise acid addition salts derived from a nitrogen in the compound of formula (I).
  • the therapeutic activity resides in the moiety derived from the compound of the invention as defined herein and the identity of the other component is of less importance although for therapeutic and prophylactic purposes it is, preferably, pharmaceutically acceptable to the patient.
  • Examples of pharmaceutically acceptable acid addition salts include those derived from mineral acids, such as hydrochloric, hydrobromic, phosphoric, metaphosphoric, nitric and sulphuric acids, and organic acids, such as tartaric, acetic, trifluoroacetic, citric, malic, lactic, fumaric, benzoic, glycollic, gluconic, succinic and methanesulphonic and arylsulphonic, for example p_- toluenesulphonic, acids.
  • mineral acids such as hydrochloric, hydrobromic, phosphoric, metaphosphoric, nitric and sulphuric acids
  • organic acids such as tartaric, acetic, trifluoroacetic, citric, malic, lactic, fumaric, benzoic, glycollic, gluconic, succinic and methanesulphonic and arylsulphonic, for example p_- toluenesulphonic, acids.
  • the present invention provides a process for the preparation of a compound of the formula (I), which process comprises the reaction of a compound of the formula (II).
  • L is a leaving group and U, X, Y and R 1 to R 6 are as hereinbefore defined.
  • Suitable leaving groups will be well known to those skilled in the art and include, for example, halo and sulphonyloxy groups such as chloro, bromo, methanesulphonyloxy and toluene-p-sulphonyloxy.
  • the reaction is conveniently carried out in the presence of a suitable inert solvent, for example a C ⁇ _4 alkanol, such as isopropanol, a halogenated hydrocarbon, an ether, an aromatic hydrocarbon or a dipolar aprotic solvent, such as acetone, at a non-extreme temperature, for example from 0 to 150°, suitably 10 to 100°C, preferably 50 to 100°C.
  • a suitable inert solvent for example a C ⁇ _4 alkanol, such as isopropanol, a halogenated hydrocarbon, an ether, an aromatic hydrocarbon or a dipolar aprotic solvent, such as acetone
  • the reaction is carried out in the presence of a base, for example an organic amine such as triethylamine, or an alkaline earth metal carbonate, hydride or hydroxide, such as sodium or potassium carbonate, hydride or hydroxide.
  • a base for example an organic amine such as triethylamine, or an alkaline earth metal carbonate, hydride or hydroxide, such as sodium or potassium carbonate, hydride or hydroxide.
  • the compound of the formula (I) may be obtained from this process in the form of a salt with the acid HL, wherein L is as hereinbefore defined, or as the free base by treating the salt with a base as hereinbefore defined.
  • one compound of formula (I) may be converted to another compound of formula (I) by chemical transformation of the appropriate substituent or substituents using appropriate chemical methods (see, for example, J. March “Advanced Organic Chemistry", Edition III, Wiley Interscience, 1985).
  • a compound containing an alkyl or aryl mercapto group may be oxidised to the corresponding sulphinyl or sulphonyl compound by use of an organic peroxide (eg benzoyl peroxide) or suitable inorganic oxidant (eg OXONE
  • a compound containing a nitro substituent may be reduced to the corresponding amino-compound, eg by use of hydrogen and an appropriate catalyst (if there are no other susceptible groups) or by use of Raney Nickel and hydrazine hydrate.
  • Amino or hydroxy substituents may be acylated by use of an acid chloride or an anhydride under appropriate conditions. Equally an acetate or amide group may be cleaved to the hydroxy or amino compound respectively by treatment with, for example dilute aqueous base.
  • amino substituent may also be converted to a dimethylamino substituent by reaction with formic acid and sodium cyanoborohydride.
  • the present invention also provides compounds of formula (I) and pharmaceutically acceptable salts thereof (hereinafter identified as the 'active ingredients') for use in medical therapy, and particularly in the treatment of disorders mediated by aberrant protein tyrosine kinase activity such as human malignancies and the other disorders mentioned above.
  • the compounds are especially useful for the treatment of disorders caused by aberrant c-erbB-2 activity such as breast, ovarian, non-small cell lung, pancreatic, gastric and colon cancers.
  • a further aspect of the invention provides a method of treatment of the human or animal body suffering from a disorder mediated by aberrant protein tyrosine kinase activity which comprises administering an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof, to the human or animal patient.
  • a further aspect of the present invention provides the use of a compound of formula (I), or a pharmaceutically acceptable salt thereof, for use in therapy.
  • a further aspect of the present invention provides the use of a compound of formula (I), or a pharmaceutically acceptable salt thereof, in the preparation of a medicament for the treatment of malignant tumours.
  • a further aspect of the present invention provides the use of a compound of formula (I), or a pharmaceutically acceptable salt thereof, in the preparation of a medicament for the treatment of atherosclerosis, restenosis or thrombosis.
  • a further aspect of the present invention provides a pharmaceutical formulation comprising one or more compounds of formula (I), or pharmaceutically acceptable salt(s) thereof, together with one or more pharmaceutically acceptable carriers.
  • the compounds or salts of the present invention Whilst it is possible for the compounds or salts of the present invention to be administered as the new chemical, it is preferred to present them in the form of a pharmaceutical formulation.
  • compositions comprising at least one compound of the formula (I) or a pharmaceutically acceptable salt thereof, together with one or more pharmaceutically acceptable carriers, diluents or excipients.
  • compositions may be presented in unit dose forms containing a predetermined amount of active ingredient per unit dose.
  • a unit may contain for example O. ⁇ mg to 1g, preferably 5mg to 100mg of a compound of the formula (I) depending on the condition being treated, the route of administration and the age, weight and condition of the patient.
  • compositions may be adapted for administration by any appropriate route, for example by the oral (including buccal or sublingual), rectal, nasal, topical (including buccal, sublingual or transdermal), vaginal or parenteral (including subcutaneous, intramuscular, intravenous or intradermal) route.
  • Such formulations may be prepared by any method known in the art of pharmacy, for example by bringing into association the active ingredient with the carrier(s) or excipient(s).
  • compositions adapted for oral administration may be presented as discrete units such as capsules or tablets; powders or granules; solutions or suspensions in aqueous or non-aqueous liquids; edible foams or whips; or oil-in- water liquid emulsions or water-in-oil liquid emulsions.
  • compositions adapted for transdermal administration may be presented as discrete patches intended to remain in intimate contact with the epidermis of the recipient for a prolonged period of time.
  • the active ingredient may be delivered from the patch by iontophoresis as generally described in Pharmaceutical Research, 3(6), 318 (1986).
  • compositions adapted for topical administration may be formulated as ointments, creams, suspensions, lotions, powders, solutions, pastes, gels, sprays, aerosols or oils.
  • the formulations are preferably applied as a topical ointment or cream.
  • the active ingredient may be employed with either a paraffinic or a water-miscible ointment base.
  • the active ingredient may be formulated in a cream with an oil-in-water cream base or a water-in-oil base.
  • compositions adapted for topical administrations to the eye include eye drops wherein the active ingredient is dissolved or suspended in a suitable carrier, especially an aqueous solvent.
  • compositions adapted for topical administration in the mouth include lozenges, pastilles and mouth washes.
  • compositions adapted for rectal administration may be presented as suppositories or as enemas.
  • compositions adapted for nasal administration wherein the carrier is a solid include a coarse powder having a particle size for example in the range 20 to 500 microns which is administered in the manner in which snuff is taken i.e. by rapid inhalation through the nasal passage from a container of the powder held close up to the nose.
  • Suitable formulations wherein the carrier is a liquid, for administration as a nasal spray or as nasal drops, include aqueous or oil solutions of the active ingredient.
  • Fine particle dusts or mists which may be generated by means of various types of metered dose pressurised aerosols, nebulizers or insufflators.
  • compositions adapted for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or spray formulations.
  • compositions adapted for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti- oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents.
  • the formulations may be presented in unit-dose or multi-dose containers, for example sealed ampoules and vials, and may be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example water for injections, immediately prior to use.
  • Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets.
  • Preferred unit dosage formulations are those containing a daily dose or sub-dose, as herein above recited, or an appropriate fraction thereof, of an active ingredient.
  • formulations may include other agents conventional in the art having regard to the type of formulation in question, for example those suitable for oral administration may include flavouring agents.
  • the compounds and salts of the formula (I) have anticancer activity as demonstrated hereinafter by their inhibition of the protein tyrosine kinase c-erbB-2 enzyme. It has thus been established that compounds of the present invention are of use in medicine and, in particular in the treatment of certain human malignancies, for example breast, ovarian non-small cell lung, pancreatic, gastric and colon cancers. Accordingly, the present invention provides a method for the treatment of susceptible malignancies in an animal, e.g. a human, which comprises administering to the animal a therapeutically effective amount of a compound or salt of the present invention. In the alternative, there is also provided a compound or salt of the present invention for use in medicine and, in particular, for use in the treatment of cancers.
  • the present invention also provides the use of a compound of formula (I) or a salt thereof for the manufacture of a medicament for treatment of malignant tumours.
  • the animal requiring treatment with a compound or salt of the present invention is usually a mammal, such as a human being.
  • a therapeutically effective amount of a compound or salt of the present invention will depend upon a number of factors including, for example, the age and weight of the animal, the precise condition requiring treatment and its severity, the nature of the formulation, and the route of administration, and will ultimately be at the discretion of the attendant phsician or veterinarian.
  • an effective amount of a compound of the present invention for the treatment of neoplastic growth, for example colon or breast carcinoma will generally be in the range of 0.1 to 100 mg kg body weight of recipient (mammal) per day and more usually in the range of 1 to 10 mg/kg body weight per day.
  • the actual amount per day would usually be from 70 to 700 mg and this amount may be given in a single dose per day or more usually in a number (such as two, three, four, five or six) of sub-doses per day such that the total daily dose is the same.
  • An effective amount of a salt of the present invention may be determined as a proportion of the effective amount of the compound per ££.
  • IR spectra were recorded on a Perkin-Elmer 257 grating spectrophotometer or a
  • Petrol refers to petroleum ether, either the fraction boiling at 40-60°C, or at 60-
  • Ether refers to diethyl ether.
  • THF refers to tetrahydrofuran
  • DMF refers to dimethylformamide
  • DCM refers to dichloromethane
  • DMSO dimethylsulphoxide
  • 4-Chloroquinazoline was prepared from 4-hydroxyquinazoline (commercially available) according to the published method (J. Org. Chem, 27, 958 (1962)). 4-Chloro-6.7-dimethoxyquinazoline was prepared in an analogous manner according to the proceedure described in European Patent Application 566 226 A1 (Zeneca Limited).
  • 5-Amino-2-(2-pyridyl)-benzimidazole was prepared according to the published method (J. Med. Chem., 22, 1113-8, (1979)).
  • 5-Amino-2-benzylbenzimidazole was prepared according to the published method (J. Het. Chem., 23, 1109-13, (1986)).
  • 5-Amino-1 -benzylbenzimidazole was prepared according to the published method (Khim. Geterotsikl. Soedin, 7, 1136-8, (1971)).
  • 5-Amino-1-benzylindazole was prepared according to the published method (FR 5600 68.01.08).
  • 5-Amino-2-phenylbenzimidazole was prepared according to the published method (J. Org. Chem., 60, 5678-82, (1995).
  • 5-Amino-1-phenylsulphonylindole was prepared according to the published method (J. Org. Chem., 55, 1379-90, (1990)).
  • 5-Nitro-3-benzylbenzimidazole and 6-nitro-3-benzvl-benzimidazole 5-nitrobenzimidazole (1 g, 6.13 mmol) in acetone (20 ml) containing potassium hydroxide pellets (1 g, 18.39 mmol) was stirred and treated with benzyl bromide (0.73 ml, 6.13 mmol). After 1h the mixture was acidified to ea pH 7, diluted with water, and extracted with ethyl acetate. The dried extracts were evaporated giving a cream solid (1.56g, 100%); m/z (M + 1) + 254.
  • uinazoline hydrochloride 4-Chloroquinazoline (0.10 g, 0.61 mmol) and 5-amino-1 -benzylindole (0.16 g, 0.73 mmol) were reacted in 2-propanol (10 ml) for 30 minutes according to the General Procedure. The bright yellow solid thus obtained was 4-(1-benzyl-5- indoylamino)quinazoline hydrochloride (0.22 g, 92%), m.p. 265-266 °C; (Found: C, 70.64; H, 4.83, N, 14.11.
  • 4-(1-Benzyl-5-indolylaminoV6.7-dimethoxyquinazoline hydrochloride 4-Chloro-6,7-dimethoxyquinazoline (0.10 g, 0.45 mmol) and 5-amino-1- be ⁇ zylindole (0.37 g, 0.63 mmol) were reacted in 2-propanol (15 ml) for 4 h according to the General Procedure. The pale yellow solid thus obtained was 4-(1-benzyl-5-indoylamino)-6,7-dimethoxyquinazoline hydrochloride (0.16 g, 78%), m.p.
  • the isomers were assigned by means of the nuclear Overhauser effect.
  • the desired product was obtained by filtration as a yellow solid (0.264 g, 84%); m/z (M+1 + ) 413; ⁇ H (d 6 -DMSO) 8.75 (IH,s), 8.20 (IH.s), 7.20-7.40 (8H,m), 6.65 (IH,d), 4.35 (2H,s), 3.97 (6H,s), 3.34 (2H,t), 2.97 (2H,t).
  • 4-M-Benzyl-6-indolylaminoV6.7-dimethoxyquinazoline hydrochloride 4-Chloro-6,7-dimethoxyquinazoline (0.031 g, 0.19 mmol) and 6-amino-1- benzylindole (0.05 g, 0.23 mmol) were reacted in 2-propanol (6.5 ml) for 30 min according to the General procedure, the light orange solid thus obtained was 4- (1-benzyl-6-indolylamino)-6,7-dimethoxyquinazoline hydrochloride (0.045 g, 62%); M.pt.
  • 4-(3-Benzyl-5-benzimidazolylaminoVquinazoline hydrochloride 4-Chloroquinazoline (0.053 g, 0.322 mmol) and 5-amino-3-benzylbenzimidazole (0.72 g, 0.322 mmol) were reacted in 2-propanol (5 ml) according to the General Procedure.
  • the desired compound was obtained by filtration as a pale yellow solid (0.05 g, 40%); m/z (M + 1 + ) 352; ⁇ H (d 6 DMSO) 9.35 (IH, s), 8.9 (2H, m), 7.5- 8.2 (6H,m), 7.3-7.5 ( 5H,m), 5.65 (2H,s).
  • the major isomer was assigned as 4-f 1 -benzyl -5-benzotriazolylamino)- 6.7-dimethoxyquinazoline and the minor isomer was assigned as 4-(3-benzyl-5- benzotriazolylamino -6.7-dimethoxvquinazoline.
  • the isomers were assigned by means of the nuclear Overhauser effect.
  • Example 20 4-(2-Phenethyl-5-indazolylaminoV6.7-dimethoxyquinazoline 4-Chloro-6,7-dimethoxyquinazoline (0.189 g, 0.842 mmol) and an isomeric mixture of 1- and 2- ⁇ henethyl-5-aminoindazole (0.200 g, 0.842 mmol) were reacted in acetonitrile (15 ml) according the General Procedure. On cooling a pale yellow precipitate was formed which was collected by filtration. This material was chromatographed on silica gel (Merck 9385, 45 g).
  • the desired product was obtained by filtration as a yellow solid (0.072 g, 50%); m/z (M + 1 + ) 339; ⁇ H (d 6 -DMSO) 8.93 (IH.s), 8.88 (IH.d), 8.78 (IH.d), 8.38 (IH,d), 7.86-8.15 (5H,m), 7.75 (IH,d), 7.55-7.64 (2H,m).
  • Biological Data Compounds of the present invention were tested for protein tyrosine kinase inhibitory activity in a substrate phosphorylation assay and a cell proliferation assay.
  • the substrate phosphorylation assay uses a baculovirus expressed, recombinant construct of the intracellular domain of c-erbB-2 that is constitutively active.
  • the method measures the ability of the isolated enzyme to catalyse the transfer of 33p.
  • the enzyme is incubated for 1 hour, at room temperature, with 100 ⁇ M ATP, 10mM MnC-2, 1mg/ml PolyGluAlaTyr (6:3:1) and test compound (diluted from a 5mM stock in DMSO, final DMSO concentration is 2%) in 40mM HEPES buffer, pH 7.4.
  • the cell proliferation assay uses an immortalised human breast epithelial cell line (HB4a) which has been transformed by over-expression of c-erbB-2. Growth of these cells in low serum is dependent upon the c-erbB-2 tyrosine kinase activity. The specificity of the effect of the test compounds on tyrosine kinase dependent growth over general toxicity is assessed by comparison to an HB4a cell line which has been transfected with ras. Cells are plated at 3000/well in 96-well plates in 0.1 ml medium and allowed to attach overnight, test compound is added in 0.1 ml medium, with a final concentration of 0.5% DMSO, and the plates incubated for 4 days at 37°C. The cells are then examined microscopically for evidence of morphological detransformation and cell mass is estimated by staining with methylene blue and measuring the absorbance at 620nm. The results are shown in Table 2 below as the IC50 values in ⁇ M.

Abstract

L'invention se rapporte à des composés hétéroaromatiques substitués inhibiteurs de protéine-tyrosine kinase, en particulier à des quinoléines et quinazolines substituées. L'invention décrit également leurs procédés de préparation, les compositions pharmaceutiques renfermant lesdits composés et leur utilisation en médecine, notamment dans le traitement du psoriasis, de la fibrose, de l'athérosclérose, de la resténose, de la maladie auto-immune, de l'allergie, de l'asthme, du rejet du greffon, de l'inflammation, de la thrombose, des maladies du système nerveux, et du cancer.
EP96925710A 1995-07-13 1996-07-11 Composes heterocycliques et compositions pharmaceutiques a base desdits composes Withdrawn EP0843671A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9514265 1995-07-13
GBGB9514265.9A GB9514265D0 (en) 1995-07-13 1995-07-13 Hetrocyclic compounds
PCT/EP1996/003026 WO1997003069A1 (fr) 1995-07-13 1996-07-11 Composes heterocycliques et compositions pharmaceutiques a base desdits composes

Publications (1)

Publication Number Publication Date
EP0843671A1 true EP0843671A1 (fr) 1998-05-27

Family

ID=10777551

Family Applications (1)

Application Number Title Priority Date Filing Date
EP96925710A Withdrawn EP0843671A1 (fr) 1995-07-13 1996-07-11 Composes heterocycliques et compositions pharmaceutiques a base desdits composes

Country Status (7)

Country Link
EP (1) EP0843671A1 (fr)
JP (1) JPH11508906A (fr)
AU (1) AU6613996A (fr)
GB (1) GB9514265D0 (fr)
HR (1) HRP960316A2 (fr)
WO (1) WO1997003069A1 (fr)
ZA (1) ZA965935B (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9353122B2 (en) 2013-02-15 2016-05-31 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof

Families Citing this family (188)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW321649B (fr) * 1994-11-12 1997-12-01 Zeneca Ltd
GB9424233D0 (en) * 1994-11-30 1995-01-18 Zeneca Ltd Quinazoline derivatives
GB9508537D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
EP0824525B1 (fr) * 1995-04-27 2001-06-13 AstraZeneca AB Derives de quinazoline
GB9508535D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivative
GB9508538D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
GB9508565D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quiazoline derivative
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
TR199801530T2 (xx) 1996-02-13 1998-11-23 Zeneca Limited VEGF �nhibit�rleri olarak kinazolin t�revleri.
GB9603095D0 (en) * 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
GB9603097D0 (en) * 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline compounds
PT885198E (pt) 1996-03-05 2002-06-28 Astrazeneca Ab Derivados de 4-anilinoquinazolina
PL190489B1 (pl) 1996-04-12 2005-12-30 Warner Lambert Co Nieodwracalne inhibitory kinaz tyrozyny, kompozycja farmaceutyczna je zawierająca i ich zastosowanie
GB9607729D0 (en) * 1996-04-13 1996-06-19 Zeneca Ltd Quinazoline derivatives
GB9707800D0 (en) 1996-05-06 1997-06-04 Zeneca Ltd Chemical compounds
EP0912559B1 (fr) 1996-07-13 2002-11-06 Glaxo Group Limited Composes heterocycliques condenses en tant qu'inhibiteurs de la proteine tyrosine kinase
JP2002505660A (ja) 1996-09-10 2002-02-19 ファルマシア・アンド・アップジョン・カンパニー 抗ウィルス剤としての８―ヒドロキシ―７―置換キノリン
DE69733825T2 (de) * 1996-09-25 2006-06-08 Astrazeneca Ab Chinolin-derivate die den effekt von wachstumsfaktoren wie vegf vezögern
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
US7863444B2 (en) 1997-03-19 2011-01-04 Abbott Laboratories 4-aminopyrrolopyrimidines as kinase inhibitors
EP1007042A4 (fr) * 1997-06-13 2001-07-04 Sugen Inc Nouveaux composes heteroaryle pour la modulation de la transduction de signaux cellulaires associee aux enzymes proteine tyrosine
DE69838172T2 (de) 1997-08-22 2008-04-10 Astrazeneca Ab Oxindolylchinazolinderivate als angiogenesehemmer
GB9800575D0 (en) * 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
RS49779B (sr) 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
US6706721B1 (en) 1998-04-29 2004-03-16 Osi Pharmaceuticals, Inc. N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate
HUP0103386A3 (en) * 1998-08-21 2002-07-29 Parker Hughes Inst St Paul Use of quinazoline derivatives for producing pharmaceutical compositions having jak 3-inhibitor effect
US6184226B1 (en) 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
US6713474B2 (en) 1998-09-18 2004-03-30 Abbott Gmbh & Co. Kg Pyrrolopyrimidines as therapeutic agents
ATE294796T1 (de) 1998-10-08 2005-05-15 Astrazeneca Ab Chinazolin derivate
GB9822450D0 (en) * 1998-10-14 1998-12-09 Smithkline Beecham Plc Medicaments
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
ATE556713T1 (de) 1999-01-13 2012-05-15 Bayer Healthcare Llc Omega-carboxyarylsubstituierte-diphenyl- harnstoffe als p38-kinasehemmer
WO2000043383A1 (fr) * 1999-01-20 2000-07-27 Smithkline Beecham P.L.C. Piperidinylquinolines utilisees comme inhibiteurs de la proteine tyrosine kinase
HU230000B1 (en) 1999-02-10 2015-04-28 Astrazeneca Ab Intermediates for the preparation of angiogenesis inhibitory quinazoline derivatives
GB9904103D0 (en) 1999-02-24 1999-04-14 Zeneca Ltd Quinoline derivatives
GB9910579D0 (en) 1999-05-08 1999-07-07 Zeneca Ltd Chemical compounds
GB9910580D0 (en) 1999-05-08 1999-07-07 Zeneca Ltd Chemical compounds
GB9914486D0 (en) 1999-06-21 1999-08-18 Smithkline Beecham Plc Medicaments
TWI262914B (en) * 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
MXPA01012887A (es) * 1999-07-07 2002-07-30 Astrazeneca Uk Ltd Derivados de quinazolina.
US6933299B1 (en) 1999-07-09 2005-08-23 Smithkline Beecham Corporation Anilinoquinazolines as protein tyrosine kinase inhibitors
WO2001004111A1 (fr) * 1999-07-09 2001-01-18 Glaxo Group Limited Anilino-quinazolines comme inhibiteurs de la proteine tyrosine kinase
GB9917406D0 (en) 1999-07-23 1999-09-22 Smithkline Beecham Plc Compounds
GB9917408D0 (en) 1999-07-23 1999-09-22 Smithkline Beecham Plc Compounds
CN1390219A (zh) 1999-09-17 2003-01-08 艾博特股份有限两合公司 作为治疗剂的吡唑并嘧啶类
US7071199B1 (en) 1999-09-17 2006-07-04 Abbott Gmbh & Cco. Kg Kinase inhibitors as therapeutic agents
UA72946C2 (uk) 1999-11-05 2005-05-16 Астразенека Аб Похідні хіназоліну як інгібітори васкулярного ендотеліального фактора росту (vegf)
US7087613B2 (en) 1999-11-11 2006-08-08 Osi Pharmaceuticals, Inc. Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride
UA74803C2 (uk) 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
US7498335B2 (en) 2000-03-06 2009-03-03 Astrazeneca Ab Method of producing an antiangiogenic or vascular permeability reducing effect
AU2001246850A1 (en) * 2000-04-06 2001-10-23 Kyowa Hakko Kogyo Co. Ltd. Diagnostics and remedies for rheumatoid arthritis
UA73993C2 (uk) 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
US7001904B1 (en) 2000-06-24 2006-02-21 Astrazeneca Ab Guanidine derivatives quinazoline and quinoline for use in the treatment of autoimmune diseases
AU2001266505A1 (en) 2000-06-28 2002-01-08 Astrazeneca Ab Substituted quinazoline derivatives and their use as inhibitors
EP1305308B1 (fr) 2000-07-26 2006-12-20 Smithkline Beecham Plc Aminopiperidine quinolines et leurs analogues azaisosteres presentant une activite antibacterienne
CA2415469A1 (fr) 2000-08-09 2002-02-14 Astrazeneca Ab Derives de la quinoline presentant une activite inhibant le facteur de croissance vegf
CA2419301C (fr) 2000-08-21 2009-12-08 Astrazeneca Ab Derives de quinazoline
AU2001293233A1 (en) 2000-09-01 2002-03-13 Chiron Corporation Aza heterocyclic derivatives and their therapeutic use
BRPI0113757B8 (pt) * 2000-09-11 2017-11-07 Chiron Corp derivados de quinolinona como inibidores de tirosina quinase
HUP0302221A3 (en) 2000-09-20 2004-01-28 Merck Patent Gmbh 4-amino-quinazolines
EP1326859A1 (fr) 2000-10-13 2003-07-16 AstraZeneca AB Derives quinazoline a activite anti-tumorale
JP3712393B2 (ja) 2000-10-20 2005-11-02 エーザイ株式会社 含窒素芳香環誘導体
AU2002212436A1 (en) * 2000-10-25 2002-05-06 Astrazeneca Ab Quinazoline derivatives
JP4564713B2 (ja) 2000-11-01 2010-10-20 ミレニアム・ファーマシューティカルズ・インコーポレイテッド 窒素性複素環式化合物、ならびに窒素性複素環式化合物およびその中間体を作製するための方法
AU2001295791A1 (en) 2000-11-02 2002-05-15 Astrazeneca Ab 4-substituted quinolines as antitumor agents
AU2002210714A1 (en) 2000-11-02 2002-06-11 Astrazeneca Ab Substituted quinolines as antitumor agents
GB0101577D0 (en) 2001-01-22 2001-03-07 Smithkline Beecham Plc Compounds
PT1370552E (pt) * 2001-03-23 2007-04-30 Bayer Pharmaceuticals Corp Inibidores de rho-quinase
ATE325795T1 (de) * 2001-03-23 2006-06-15 Bayer Corp Rho-kinase inhibitoren
US6982274B2 (en) 2001-04-16 2006-01-03 Eisai Co., Ltd. 1H-indazole compound
ES2312557T3 (es) 2001-04-19 2009-03-01 Astrazeneca Ab Derivados de quinazolina.
GB0112834D0 (en) 2001-05-25 2001-07-18 Smithkline Beecham Plc Medicaments
US7829566B2 (en) 2001-09-17 2010-11-09 Werner Mederski 4-amino-quinazolines
KR100810468B1 (ko) * 2001-10-10 2008-03-07 씨제이제일제당 (주) 사이클로옥시게나제-2의 저해제로서 선택성이 뛰어난1ｈ-인돌 유도체
CN100343238C (zh) * 2001-11-03 2007-10-17 阿斯特拉曾尼卡有限公司 用作抗肿瘤药物的喹唑啉衍生物
GB0126433D0 (en) * 2001-11-03 2002-01-02 Astrazeneca Ab Compounds
WO2003055866A1 (fr) * 2001-12-21 2003-07-10 Bayer Pharmaceuticals Corporation Composes derives de quinazoline et de quinoline servant d'inhibiteurs de prolylpeptidase, d'inducteurs d'apoptose et d'agents therapeutiques anticancereux
MXPA04006260A (es) 2001-12-24 2005-03-31 Astrazeneca Ab Derivados de quinazolina sustituidos como inhibidores de cinasas aurora.
AU2003202263A1 (en) 2002-01-10 2003-07-30 Bayer Healthcare Ag Roh-kinase inhibitors
EP1470121B1 (fr) 2002-01-23 2012-07-11 Bayer HealthCare LLC Derives pyrimidine en tant qu'inhibiteurs de kinase rho
MXPA04007196A (es) 2002-01-23 2005-06-08 Bayer Pharmaceuticals Corp Inhibidores de rho-quinasa.
EP1470125A1 (fr) 2002-01-29 2004-10-27 Glaxo Group Limited Derives aminopiperidine
WO2003064431A2 (fr) 2002-01-29 2003-08-07 Glaxo Group Limited Composes aminopiperidine, leur procede de preparation et compositions pharmaceutiques les contenant
AU2003202094B2 (en) * 2002-02-01 2009-10-08 Astrazeneca Ab Quinazoline compounds
EP2324825A1 (fr) 2002-02-11 2011-05-25 Bayer Healthcare LLC Arylurées dotées d'une activité d'inhibition de l'angiogenèse
TW200302722A (en) * 2002-02-13 2003-08-16 Astrazeneca Ab Therapeutic agents
US7645878B2 (en) * 2002-03-22 2010-01-12 Bayer Healthcare Llc Process for preparing quinazoline Rho-kinase inhibitors and intermediates thereof
US6924285B2 (en) 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
DE60327323D1 (de) 2002-07-09 2009-06-04 Astrazeneca Ab Chinazoline derivative und ihre anwendung in der krebsbehandlung
GB0215823D0 (en) 2002-07-09 2002-08-14 Astrazeneca Ab Quinazoline derivatives
AU2003249212C1 (en) 2002-07-15 2011-10-27 Symphony Evolution, Inc. Receptor-type kinase modulators and methods of use
CA2494061C (fr) 2002-07-31 2011-06-14 Wayne R. Danter Inhibiteurs de proteine tyrosine kinase
EP2573079A3 (fr) 2002-08-23 2015-03-11 Novartis AG Dérivés de benzimidazoles quinolinones et leurs utilisations
US7825132B2 (en) 2002-08-23 2010-11-02 Novartis Vaccines And Diagnostics, Inc. Inhibition of FGFR3 and treatment of multiple myeloma
EP1551824B1 (fr) 2002-10-09 2007-12-12 Critical Outcome Technologies, Inc. Inhibiteurs de proteine tyrosine kinase
WO2004041277A1 (fr) * 2002-11-01 2004-05-21 Merck & Co., Inc. Derives de carbonylamino-benzimidazole utilises comme modulateurs du recepteur androgene
GB0225579D0 (en) 2002-11-02 2002-12-11 Astrazeneca Ab Chemical compounds
CN100354278C (zh) * 2002-11-04 2007-12-12 阿斯利康(瑞典)有限公司 作为src酪氨酸激酶抑制剂的喹唑啉衍生物
JP4593464B2 (ja) * 2002-11-04 2010-12-08 アストラゼネカ アクチボラグ Ｓｒｃチロシンキナーゼ阻害剤としてのキナゾリン誘導体
WO2004043389A2 (fr) 2002-11-13 2004-05-27 Chiron Corporation Procedes de traitement du cancer et procedes connexes
DE10260730A1 (de) 2002-12-23 2004-07-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue substituierte stickstoffhaltige Heterobicyclen, deren Herstellung und deren Verwendung als Arzneimittel
US7429597B2 (en) 2002-12-23 2008-09-30 Boehringer Ingelheim Pharma Gmbh & Co., Kg Substituted nitrogen-containing heterobicycles, the preparation thereof and their use as pharmaceutical compositions
ATE438644T1 (de) 2002-12-24 2009-08-15 Astrazeneca Ab Chinazolinderivate
GB0307333D0 (en) * 2003-03-29 2003-05-07 Astrazeneca Ab Therapeutic agent
GB0309009D0 (en) * 2003-04-22 2003-05-28 Astrazeneca Ab Quinazoline derivatives
GB0309850D0 (en) 2003-04-30 2003-06-04 Astrazeneca Ab Quinazoline derivatives
PT1626714E (pt) 2003-05-20 2007-08-24 Bayer Pharmaceuticals Corp Diarilureias para doenças mediadas por pdgfr
GB0317665D0 (en) 2003-07-29 2003-09-03 Astrazeneca Ab Qinazoline derivatives
GB0318422D0 (en) * 2003-08-06 2003-09-10 Astrazeneca Ab Chemical compounds
PL1667991T3 (pl) 2003-09-16 2008-12-31 Astrazeneca Ab Pochodne chinazoliny jako inhibitory kinazy tyrozynowej
GB0322409D0 (en) 2003-09-25 2003-10-29 Astrazeneca Ab Quinazoline derivatives
EP2213661B1 (fr) 2003-09-26 2011-07-20 Exelixis Inc. Modulateurs c-Met et produits d'utilisation
US7683172B2 (en) 2003-11-11 2010-03-23 Eisai R&D Management Co., Ltd. Urea derivative and process for preparing the same
GB0326459D0 (en) 2003-11-13 2003-12-17 Astrazeneca Ab Quinazoline derivatives
NZ547009A (en) 2003-12-23 2009-09-25 Pfizer Novel quinoline derivatives
GB0330043D0 (en) 2003-12-24 2004-01-28 Pharmacia Italia Spa Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions comprising them
GB0330042D0 (en) 2003-12-24 2004-01-28 Pharmacia Italia Spa Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions them
GB0330002D0 (en) 2003-12-24 2004-01-28 Astrazeneca Ab Quinazoline derivatives
JP2007518823A (ja) 2004-01-23 2007-07-12 アムゲン インコーポレイテッド キノリン、キナゾリン、ピリジン、及びピリミジン化合物と炎症、血管新生、及び癌に対する治療におけるそれら化合物の用途
TW200536851A (en) 2004-01-23 2005-11-16 Amgen Inc Compounds and methods of use
WO2005075439A1 (fr) 2004-02-03 2005-08-18 Astrazeneca Ab Derives de quinazoline
JP5019884B2 (ja) 2004-02-20 2012-09-05 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 炎症プロセスおよび転移プロセスの調節
DK1746999T3 (da) 2004-05-06 2012-01-23 Warner Lambert Co 4-phenylamino-quinazolin-6-yl-amider
WO2005118572A1 (fr) * 2004-06-04 2005-12-15 Astrazeneca Ab Derives de quinazoline utilises comme tyrosine kinases du recepteur erbb
US7452887B2 (en) 2004-06-04 2008-11-18 Amphora Discovery Corporation Quinoline- and isoquinoline-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof
ATE428421T1 (de) 2004-09-17 2009-05-15 Eisai R&D Man Co Ltd Medizinische zusammensetzung mit verbesserter stabilität und reduzierten gelierungseigenschaften
WO2006040520A1 (fr) * 2004-10-12 2006-04-20 Astrazeneca Ab Derives de quinazoline
MX2007006230A (es) 2004-11-30 2007-07-25 Amgen Inc Quinolinas y analogos de quinazolinas y su uso como medicamentos para tratar cancer.
JP4881875B2 (ja) 2004-12-14 2012-02-22 アストラゼネカ アクチボラグ 抗腫瘍剤としてのピラゾロピリミジン化合物
EP1863792B1 (fr) 2005-03-28 2009-01-21 Brystol-Myers Squibb Company Inhibiteurs de kinase exercant une action antiproliferative
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
GB0508715D0 (en) * 2005-04-29 2005-06-08 Astrazeneca Ab Chemical compounds
MX2007014206A (es) 2005-05-13 2008-02-07 Novartis Ag Metodos para tratar cancer resistente a los farmacos.
MX2007014381A (es) 2005-05-17 2008-02-06 Novartis Ag Metodos para sintetizar compuestos heterociclicos.
EP2270000B1 (fr) 2005-05-23 2015-07-29 Novartis AG Formes cristallines et autres de sels d'acide lactique 4-amino-5-fluoro-3-[6-(4-méthylpipérazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one
JP2009501235A (ja) * 2005-07-15 2009-01-15 シェーリング コーポレイション 癌処置において有用なキナゾリン誘導体
US9006240B2 (en) 2005-08-02 2015-04-14 Eisai R&D Management Co., Ltd. Method for assay on the effect of vascularization inhibitor
JP2009508918A (ja) 2005-09-20 2009-03-05 アストラゼネカ アクチボラグ 癌治療のためのｅｒｂＢ受容体チロシンキナーゼ阻害剤としての４−（１Ｈ−インダゾール−５−イル］アミノ）キナゾリン化合物
US7820821B2 (en) * 2006-02-10 2010-10-26 Transtech Pharma, Inc. Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors
UY30183A1 (es) 2006-03-02 2007-10-31 Astrazeneca Ab Derivados de quinolina
US20090209580A1 (en) 2006-05-18 2009-08-20 Eisai R & D Management Co., Ltd. Antitumor agent for thyroid cancer
US8865737B2 (en) 2006-08-28 2014-10-21 Eisai R&D Management Co., Ltd. Antitumor agent for undifferentiated gastric cancer
EP1921070A1 (fr) 2006-11-10 2008-05-14 Boehringer Ingelheim Pharma GmbH & Co. KG heterocycles bicycliques, medicaments á base de ces composes, leur usage et procédé pour leur preparation
US8138191B2 (en) 2007-01-11 2012-03-20 Critical Outcome Technologies Inc. Inhibitor compounds and cancer treatment methods
CN101600694A (zh) 2007-01-29 2009-12-09 卫材R&D管理有限公司 未分化型胃癌治疗用组合物
EA200901041A1 (ru) 2007-02-06 2010-02-26 Бёрингер Ингельхайм Интернациональ Гмбх Бициклические гетероциклы, содержащие эти соединения лекарственные средства, их применение и способ их получения
US8288377B2 (en) * 2007-09-21 2012-10-16 Janssen Pharmaceutica N.V. Inhibitors of the interaction between MDM2 and p53
WO2009058267A2 (fr) 2007-10-29 2009-05-07 Amgen Inc. Dérivés de benzomorpholine et procédés d'utilisation
MX2010004625A (es) 2007-10-29 2010-05-20 Natco Pharma Ltd Nuevos derivados de 4(tetrazol-5-il)-quinazolina como agentes anticancerosos.
KR101513326B1 (ko) 2007-11-09 2015-04-17 에자이 알앤드디 매니지먼트 가부시키가이샤 혈관 신생 저해 물질과 항종양성 백금 착물의 병용
EP2225226B1 (fr) 2007-12-26 2016-08-17 Critical Outcome Technologies, Inc. Composés et leur utilisation dans un procédé pour le traitement du cancer
AU2009211523B2 (en) 2008-02-07 2014-03-13 Boehringer Ingelheim International Gmbh Spirocyclic heterocycles, medicaments containing said compounds, use thereof and method for their production
JP5739802B2 (ja) 2008-05-13 2015-06-24 アストラゼネカ アクチボラグ ４−（３−クロロ−２−フルオロアニリノ）−７−メトキシ−６−｛［１−（ｎ−メチルカルバモイルメチル）ピペリジン−４−イル］オキシ｝キナゾリンのフマル酸塩
US8648191B2 (en) 2008-08-08 2014-02-11 Boehringer Ingelheim International Gmbh Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them
TWI641593B (zh) 2009-01-16 2018-11-21 美商艾克塞里克斯公司 包含ｎ-（４-｛〔６，７-雙（甲氧基）喹啉-４-基〕氧基｝苯基）-ｎ’-（４-氟苯基）環丙烷-１，１-二甲醯胺之蘋果酸鹽之醫藥組合物及其用途
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
NZ598516A (en) 2009-09-03 2013-02-22 Bristol Myers Squibb Co Quinazolines as potassium ion channel inhibitors
CA2999435A1 (fr) 2010-04-01 2011-10-06 Critical Outcome Technologies Inc. Composes et methodes pour le traitement du vih
EP2586443B1 (fr) 2010-06-25 2016-03-16 Eisai R&D Management Co., Ltd. Agent anticancéreux utilisant des composés ayant un effet inhibiteur de kinase en combinaison
BR112013002212A2 (pt) * 2010-07-29 2017-09-26 Merck Patent Gmbh carboxamidas aza-heterocíclicas de aminas cíclicas
JP6006242B2 (ja) 2011-03-04 2016-10-12 ニューゲン セラピューティクス， インコーポレイテッド アルキン置換キナゾリン化合物および使用方法
KR101762999B1 (ko) 2011-04-18 2017-07-28 에자이 알앤드디 매니지먼트 가부시키가이샤 종양 치료제
US9945862B2 (en) 2011-06-03 2018-04-17 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
CN102942561A (zh) * 2012-11-06 2013-02-27 深圳海王药业有限公司 4-氨基喹唑啉杂环化合物及其用途
WO2014098176A1 (fr) 2012-12-21 2014-06-26 エーザイ・アール・アンド・ディー・マネジメント株式会社 Forme amorphe de dérivé de quinoline et son procédé de production
AU2014219024B2 (en) 2013-02-20 2018-04-05 KALA BIO, Inc. Therapeutic compounds and uses thereof
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
EA027811B1 (ru) 2013-04-04 2017-09-29 Янссен Фармацевтика Нв ПРОИЗВОДНЫЕ N-(2,3-ДИГИДРО-1H-ПИРРОЛО[2,3-b]ПИРИДИН-5-ИЛ)-4-ХИНАЗОЛИНАМИНА И N-(2,3-ДИГИДРО-1H-ИНДОЛ-5-ИЛ)-4-ХИНАЗОЛИНАМИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PERK
NZ714049A (en) 2013-05-14 2020-05-29 Eisai R&D Man Co Ltd Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
AR096654A1 (es) 2013-06-20 2016-01-27 Ab Science Derivados de benzimidazol como inhibidores selectivos de proteína quinasa
SI3311845T1 (sl) 2013-09-16 2020-06-30 Astrazeneca Ab Terapevtski polimerni nanodelci in postopki njihove izdelave in uporabe
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
MX355330B (es) 2013-11-01 2018-04-16 Kala Pharmaceuticals Inc Formas cristalinas de compuestos terapeuticos y sus usos.
TR201904658T4 (tr) * 2014-04-04 2019-04-22 Pfizer Bisiklik füzyonla birleştirilmiş heteroaril veya aril bileşikleri ve bunların ırak4 inhibitörleri olarak kullanımları.
CA2957005C (fr) 2014-08-28 2021-10-12 Eisai R&D Management Co., Ltd. Derive de quinoline de purete elevee et son procede de fabrication
PL3263106T3 (pl) 2015-02-25 2024-04-02 Eisai R&D Management Co., Ltd. Sposób tłumienia goryczy pochodnej chinoliny
KR20170122809A (ko) 2015-03-04 2017-11-06 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
CN104725364B (zh) * 2015-03-12 2017-09-15 江苏省中国科学院植物研究所 6,7‑二甲氧基‑喹唑啉‑4‑胺衍生物、其制备方法及医药用途
WO2016204193A1 (fr) 2015-06-16 2016-12-22 株式会社ＰＲＩＳＭ Ｐｈａｒｍａ Agent anticancéreux
KR20180086187A (ko) 2015-10-05 2018-07-30 더 트러스티이스 오브 콜롬비아 유니버시티 인 더 시티 오브 뉴욕 자가포식 유동의 활성체 및 포스포리파제 d 및 타우를 포함하는 단백질 응집물의 클리어런스 및 단백질질환의 치료
CN106045980B (zh) * 2016-06-03 2017-11-03 江苏开放大学 一种喹唑啉衍生物及其制备方法
EP3509422A4 (fr) 2016-09-08 2020-05-20 Kala Pharmaceuticals, Inc. Formes cristallines de composés thérapeutiques et leurs utilisations
AU2017324716B2 (en) 2016-09-08 2020-08-13 KALA BIO, Inc. Crystalline forms of therapeutic compounds and uses thereof
EP3509421A4 (fr) 2016-09-08 2020-05-20 Kala Pharmaceuticals, Inc. Formes cristallines de composés thérapeutiques et leurs utilisations
ES2888298T3 (es) 2017-04-27 2022-01-03 Astrazeneca Ab Compuestos de C5-anilinoquinazolina y su uso en el tratamiento de cáncer
JP7117323B2 (ja) * 2017-04-27 2022-08-12 アストラゼネカ・アクチエボラーグ フェノキシキナゾリン化合物及び癌の処置におけるそれらの使用
KR20240017986A (ko) * 2017-09-26 2024-02-08 더 리전트 오브 더 유니버시티 오브 캘리포니아 암 치료를 위한 조성물 및 방법
FR3080620B1 (fr) * 2018-04-27 2021-11-12 Univ Paris Sud Composes a activite inhibitrice de la polymerisation de la tubuline et aux proprietes immunomodulatrices

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5710158A (en) * 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
GB9323290D0 (en) * 1992-12-10 1994-01-05 Zeneca Ltd Quinazoline derivatives
TW321649B (fr) * 1994-11-12 1997-12-01 Zeneca Ltd

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9703069A1 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9353122B2 (en) 2013-02-15 2016-05-31 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US9827248B2 (en) 2013-02-15 2017-11-28 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US9877970B2 (en) 2013-02-15 2018-01-30 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US10398703B2 (en) 2013-02-15 2019-09-03 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US10966987B2 (en) 2013-02-15 2021-04-06 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof

Also Published As

Publication number Publication date
HRP960316A2 (en) 1998-02-28
JPH11508906A (ja) 1999-08-03
GB9514265D0 (en) 1995-09-13
AU6613996A (en) 1997-02-10
WO1997003069A1 (fr) 1997-01-30
ZA965935B (en) 1998-02-12

Similar Documents

Publication Publication Date Title
EP0843671A1 (fr) Composes heterocycliques et compositions pharmaceutiques a base desdits composes
US6174889B1 (en) Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors
US6207669B1 (en) Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors
US6828320B2 (en) Heterocyclic compounds
US6169091B1 (en) Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors
EP1047694B1 (fr) Composes heteroaromatiques bicycliques agissant comme inhibiteurs de la tyrosine kinase
WO1997013760A1 (fr) Composes condenses tricycliques et compositions pharmaceutiques les contenant
US5770599A (en) Quinazoline derivatives
WO1999035132A1 (fr) Composes heterocycliques
KR20100015353A (ko) Ｊａｋ３ 억제제로서의 피롤로피리미딘 유도체
JP2002530385A (ja) 置換４−アミノ−２−アリールシクロペンタ［ｄ］ピリミジン、それらの製造、それらの使用およびそれらを含有する医薬製剤
US6964977B2 (en) Oxindole derivatives
MXPA99000483A (en) Biciclic heteroaromatic compounds as protein inhibitors tirosin cin

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19980109

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20000217

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20000628